LA-Azepane
Pharmaceutical compound
From Wikipedia, the free encyclopedia
LA-Azepane, or LSD-Azepane, also known as lysergic acid azepane or as lysergic acid hexamethylene imide, is a chemical compound of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is an derivative of LSD in which the N,N-diethylamide moiety has been cyclized to form an azepane ring.[1] The compound is very little studied and described itself, but is closely related to other amide-cyclized LSD analogues including LA-Pip, LSM-775 (LA-Morph), LPD-824 (LA-Pyr), LPN, LSZ (LA-Azetidide), and LA-Aziridine, among others.[2][3] The chemical synthesis of the compound has been described.[1] LA-Azepane was first described in the literature in a patent by Richard P. Pioch at Eli Lilly and Company in 1961.[1] The patent had been filed 5 years previously in 1956.[1]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | LSD-Azepane; Lysergic acid azepane; Lysergic acid hexamethylene imide; N-(Azepan-1-yl)lysergamide |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H27N3O |
| Molar mass | 349.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
